Nexalis Therapeutics Limited (ASX:NX1)
Australia · Delayed Price · Currency is AUD 0.0250
0.00 (0.00%)
At close: Mar 3, 2026
Nexalis Therapeutics Company Description
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia.
It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD).
The company was formerly known as InhaleRx Limited and changed its name Nexalis Therapeutics Limited in January 2026.
Nexalis Therapeutics Limited was incorporated in 2016 and is headquartered in Melbourne, Australia.
Nexalis Therapeutics Limited
| Country | Australia |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Darryl Davies |
Contact Details
Address: 505 Little Collins Street Melbourne, VIC 3000 Australia | |
| Phone | 61 3 8678 4091 |
| Website | inhalerx.com.au |
Stock Details
| Ticker Symbol | NX1 |
| Exchange | Australian Securities Exchange |
| Fiscal Year | January - December |
| Reporting Currency | AUD |
| ISIN Number | AU0000456733 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Darryl Davies B.Sc. | Chief Executive Officer |
| Dr. Robert Jenny B.A., B.Sc., Ph.D. | Chief Scientific Officer |
| James Stephen Barrie CPA | Company Secretary |
| Greg Hammond | Chief Financial Officer |
| Srinivasa Rao Suryadevara | Executive Vice President |